Start-Up Nation Finder

45 companies were selected

Add smartlist note (optional)

Smartlist name*

Smartlist must have a valid name.

Description (optional)

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME# ’s profile to become an administrator with editing privileges in
#COMPANY_NAME# ’s page on Start-Up Nation Finder

The invitation to claim the profile was originally sent to

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME# ’s profile to become an administrator with editing privileges in
#COMPANY_NAME# ’s page on Start-Up Nation Finder

Please provide us the following information. Note that you need to have an email in this organization in order to claim the profile.

Name*

Work Email* (please provide your email in the organization)

Position*

Notes

I agree to receive Informational Emails from Start-Up Nation Finder as defined in the Privacy Policy and Terms of Use

Already have an account?

Search Was Saved

Home > Companies > Tarsier Pharma

Claimed by owner • Last Update 23.2.2023 • Suggest Edits • Claim Profile

Claimed by owner

Tarsier Pharma

Former names: Tarsius Pharma

Novel Treatments for Autoimmune Inflammatory Ocular Diseases

Tarsier Pharma

www.prnewswire.com • Aug 15, 2022

Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation

www.calcalistech.com • Feb 4, 2022

How one female CEO overcame adversity to find a cure for Uveitis

www.prnewswire.com • Jan 5, 2022

Tarsier™ Pharma is launching a dedicated website about uveitic glaucoma

www.timesofisrael.com • Dec 1, 2021

Israeli pharmaceutical executive wins 2021 EU Prize for Women Innovators

www.prnewswire.com • Aug 24, 2021

Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial

www.biospace.com • Dec 17, 2020

Tarsier Pharma's Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for TRS01 Phase III Program in Uveitis BioSpace

www.prnewswire.com • Oct 5, 2020

Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitis

www.prnewswire.com • Jun 22, 2020

Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis

www.prnewswire.com • Nov 19, 2019

Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agency

www.prnewswire.com • Sep 24, 2019

Tarsius Pharma Announces FDA Acceptance of IND Application for TRS01

www.calcalistech.com • Sep 18, 2019

Tarsius Pharma Receives 2.4 Million Euros EU Grant to Combat Blinding Diseases

www.dealstreetasia.com • Sep 11, 2018

Sun Pharma to acquire 18.75% stake in Israel's Tarsius for $3m

Tarsier Pharma is a late-clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune inflammatory ocular diseases.

The TRS Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases. It is currently being developed as both eye drops and intravitreal injections. TRS has the potential to effectively control a range of autoimmune and inflammatory ocular diseases as potently as steroids but without the negative side effects.

The company's investors include a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, BioLight Life Sciences Ltd, as well as private investors and family offices.

The company has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 879598.